Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation. 1992

G Trinchieri, and M Wysocka, and A D'Andrea, and M Rengaraju, and M Aste-Amezaga, and M Kubin, and N M Valiante, and J Chehimi
Wistar Institute, Philadelphia, PA 19104.

Natural Killer cell Stimulatory Factor (NKSF) or interleukin-12 (IL-12) is a heterodimeric cytokine of 70 kDa formed by a heavy chain of 40 kDa (p40) and a light chain of 35 kDa (p35). Although it was originally identified and purified from the supernatant of Epstein-Barr virus-transformed B cell lines, it has been shown that among peripheral blood cells NKSF/IL-12 is predominantly produced by monocytes, with lower production by B cells and other accessory cells. The most powerful inducers of NKSF/IL-12 production are bacteria, bacterial products and parasites. In addition to the biologically active p70 heterodimer, the cells producing NKSF/IL-12 also secrete a large excess of monomeric p40, a molecule with no demonstrable biological activity. NKSF/IL-12 is active on T lymphocytes and NK cells on which it induces production of lymphokines, enhancement of cytotoxic activity and mitogenic effects. NKSF/IL-12 induces T and NK cells to produce IFN-gamma and synergizes with other IFN-gamma inducers in this effect. In vitro, and probably in vivo, NKSF/IL-12 is required for optimal IFN-gamma production. When human lymphocytes are stimulated with antigens in vitro, addition of exogenous NKSF/IL-12 to the culture induces differentiation of T helper type 1 (Th1) cells, whereas neutralization of endogenous NKSF/IL-12 with antibodies favors differentiation of Th2 cells. IFN-gamma, a product of Th1 cells, enhances NKSF/IL-12 production by mononuclear cells, whereas IL-10 and IL-4, products of Th2 cells, efficiently inhibit it. Therefore, NKSF/IL-12 appears to be an important inducer of Th1 responses produced by accessory cells during early antigenic stimulation and its production is regulated by a positive feedback mechanism mediated by Th1 cells through IFN-gamma and a negative one by Th2 cells through IL-10 and IL-4. The balance of IL-12 production versus IL-10 and IL-4 production early during an immune response might therefore be instrumental in determining Th1-type versus Th2-type immune responses. Because of this potential role of IL-12 during immune responses, our results demonstrating the impaired ability of HIV seropositive patients to produce NKSF/IL-12 in response to bacterial stimulation suggest that this defect in NKSF/IL-12 production might be a factor contributing to their immune depression.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D007378 Interleukins Soluble factors which stimulate growth-related activities of leukocytes as well as other cell types. They enhance cell proliferation and differentiation, DNA synthesis, secretion of other biologically active molecules and responses to immune and inflammatory stimuli. Interleukin
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D006133 Growth Substances Signal molecules that are involved in the control of cell growth and differentiation. Mitogens, Endogenous,Endogenous Mitogens
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D018664 Interleukin-12 A heterodimeric cytokine that plays a role in innate and adaptive immune responses. Interleukin-12 is a 70 kDa protein that is composed of covalently linked 40 kDa and 35 kDa subunits. It is produced by DENDRITIC CELLS; MACROPHAGES and a variety of other immune cells and plays a role in the stimulation of INTERFERON-GAMMA production by T-LYMPHOCYTES and NATURAL KILLER CELLS. Edodekin Alfa,IL-12,Natural Killer Cell Stimulatory Factor,Cytotoxic Lymphocyte Maturation Factor,IL 12,IL-12 p70,IL12,Interleukin 12,Interleukin-12 p70,Interleukin 12 p70

Related Publications

G Trinchieri, and M Wysocka, and A D'Andrea, and M Rengaraju, and M Aste-Amezaga, and M Kubin, and N M Valiante, and J Chehimi
April 1991, The Journal of surgical research,
G Trinchieri, and M Wysocka, and A D'Andrea, and M Rengaraju, and M Aste-Amezaga, and M Kubin, and N M Valiante, and J Chehimi
August 1993, European journal of immunology,
G Trinchieri, and M Wysocka, and A D'Andrea, and M Rengaraju, and M Aste-Amezaga, and M Kubin, and N M Valiante, and J Chehimi
March 1992, The Journal of experimental medicine,
G Trinchieri, and M Wysocka, and A D'Andrea, and M Rengaraju, and M Aste-Amezaga, and M Kubin, and N M Valiante, and J Chehimi
November 1992, The Journal of experimental medicine,
G Trinchieri, and M Wysocka, and A D'Andrea, and M Rengaraju, and M Aste-Amezaga, and M Kubin, and N M Valiante, and J Chehimi
July 1991, Cell,
G Trinchieri, and M Wysocka, and A D'Andrea, and M Rengaraju, and M Aste-Amezaga, and M Kubin, and N M Valiante, and J Chehimi
January 1992, Journal of immunology (Baltimore, Md. : 1950),
G Trinchieri, and M Wysocka, and A D'Andrea, and M Rengaraju, and M Aste-Amezaga, and M Kubin, and N M Valiante, and J Chehimi
September 1989, The Journal of experimental medicine,
G Trinchieri, and M Wysocka, and A D'Andrea, and M Rengaraju, and M Aste-Amezaga, and M Kubin, and N M Valiante, and J Chehimi
July 1994, Scandinavian journal of immunology,
G Trinchieri, and M Wysocka, and A D'Andrea, and M Rengaraju, and M Aste-Amezaga, and M Kubin, and N M Valiante, and J Chehimi
January 1995, Japanese journal of cancer research : Gann,
G Trinchieri, and M Wysocka, and A D'Andrea, and M Rengaraju, and M Aste-Amezaga, and M Kubin, and N M Valiante, and J Chehimi
November 1992, Cellular immunology,
Copied contents to your clipboard!